News Conference News AHA 2024 SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity Michael O'Riordan November 16, 2024
News Conference News ACC 2024 STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed L.A. McKeown April 06, 2024
News Daily News Universal Risk Tool Works Well in Both Primary and Secondary Prevention Michael O'Riordan February 01, 2024
News Daily News Bempedoic Acid Reassures in Patients With and Without Diabetes: CLEAR Outcomes Michael O'Riordan December 08, 2023
News Daily News Acute MI Patients Without Standard CVD Risk Factors at Higher Risk of Death Michael O'Riordan July 07, 2023
News Conference News ADA 2023 Big Reductions in ASCVD Events With Bempedoic Acid in Primary Prevention Michael O'Riordan June 28, 2023
News Conference News AHA 2022 Common ‘Heart’ Supplements Can’t Beat Statins: SPORT Michael O'Riordan November 06, 2022
News Daily News FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl Michael O'Riordan November 14, 2019
News Conference News EAS 2019 Bempedoic Acid/Ezetimibe Combo Lowers LDL Cholesterol in High-Risk Patients Michael O'Riordan May 30, 2019
News Daily News Women Without Diabetes Fare as Poorly as Diabetic Men Post-PCI L.A. McKeown January 30, 2017
News Daily News Weight Loss May Affect Diabetes Risk, but Not Future CVD Outlook L.A. McKeown August 04, 2016
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Conference News AHA 2012 EMPIRE: Exenatide Cardioprotective in STEMI Patients Receiving DES Jason Kahn November 04, 2012